4-(4-fluoro-3-nitrophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one | 115621-60-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-fluoro-3-nitrophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one
• 英文别名: 3-(4-fluoro-3-nitrophenyl)-4-methyl-1,2-dihydropyrrol-5-one
• CAS: 115621-60-8
• 化学式: C₁₁H₉FN₂O₃
• 分子量: 236.202
• InChiKey: BBCKNQUCCIBWHB-UHFFFAOYSA-N

物化性质

• 沸点：
  462.4±45.0 °C(Predicted)
• 密度：
  1.383±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-fluoro-3-nitrophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one 在 盐酸 、 次磷酸 、 tin(ll) chloride 、 copper(II) oxide 、 sodium nitrite 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 8.5h， 生成 1,5-dihydro-3-methyl-4-[4-(2-methyl-1 H-imidazol-1-yl)phenyl]-2 H-pyrrol-2-one
  参考文献：
  名称：

  (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase

  摘要：

  Seven 3-alkyl-4-aryl-1,5-dihydro-2H-pyrrol-2-ones were prepared as potential inhibitors of cardiac cAMP phosphodiesterase (PDE). The design of these compounds made use of rolipram, a known inhibitor of the brain cAMP PDE isozyme, as a lead structure and was guided by a model which describes the features required for potent inhibition of the cardiac isozyme. Syntheses for the new compounds are described, together with the results of theoretical and crystallographic studies aimed toward ascertaining their three-dimensional structures. The activities of these compounds as inhibitors of the cardiac and brain cAMP PDE isozymes and their positive inotropic activity in ferret papillary muscle are also reported. Selected compounds were further examined in an in vivo hemodynamic model. One compound,1,5-dihydro-4-[4-(1H-imidazol-1-yl)phenyl]-3-methyl-2H-pyrrol-2-one, was identified as a potent and selective positive inotropic agent and inhibitor of cardiac cAMP PDE.

  DOI：

  10.1021/jm00060a012
• 作为产物：
  描述：

  4-(4-fluorophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one 在 硫酸 、 硝酸 作用下， 反应 1.0h， 以71%的产率得到4-(4-fluoro-3-nitrophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one
  参考文献：
  名称：

  (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase

  摘要：

  Seven 3-alkyl-4-aryl-1,5-dihydro-2H-pyrrol-2-ones were prepared as potential inhibitors of cardiac cAMP phosphodiesterase (PDE). The design of these compounds made use of rolipram, a known inhibitor of the brain cAMP PDE isozyme, as a lead structure and was guided by a model which describes the features required for potent inhibition of the cardiac isozyme. Syntheses for the new compounds are described, together with the results of theoretical and crystallographic studies aimed toward ascertaining their three-dimensional structures. The activities of these compounds as inhibitors of the cardiac and brain cAMP PDE isozymes and their positive inotropic activity in ferret papillary muscle are also reported. Selected compounds were further examined in an in vivo hemodynamic model. One compound,1,5-dihydro-4-[4-(1H-imidazol-1-yl)phenyl]-3-methyl-2H-pyrrol-2-one, was identified as a potent and selective positive inotropic agent and inhibitor of cardiac cAMP PDE.

  DOI：

  10.1021/jm00060a012

文献信息

• Cardiotonic imidazolylphenylpyrrol-2-ones
  申请人：Schering A.G.

  公开号：US04737511A1

  公开（公告）日：1988-04-12

  Novel imidazolylphenylpyrrol-2-ones are described as having cardiovascular properties especially as cardiotonic agents in the treatment of congestive heart failure. Pharmaceutical formulations containing such compounds are also described.

  小说咪唑基苯基吡咯-2-酮被描述为具有心血管特性，特别是作为心力衰竭治疗中的强心剂。还描述了含有这些化合物的药物制剂。
• CARDIOTONIC IMIDAZOLYLPHENYLPYRROL-2-ONES
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0329691B1

  公开（公告）日：1991-11-21
• US4737511A
  申请人：——

  公开号：US4737511A

  公开（公告）日：1988-04-12
• [EN] CARDIOTONIC IMIDAZOLYLPHENYLPYRROL-2-ONES
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：WO1988003531A1

  公开（公告）日：1988-05-19

  (EN) Imidazolylphenylpyrrol-2-ones of one of the formulae (I) and (II), having cardiovascular properties especially as cardiotonic agents in the treatment of congestive heart failure, and pharmaceutical formulations containing such compounds.(FR) Des imidazolylphénylpyrrol-2-ones ayant l'une des formules (I) et (II) présentent des propriétés cardiovasculaires, notamment à titre d'agents cardiotoniques dans le traitement de l'insuffisance cardiaque. Sont également décrites des formulations pharmaceutiques contenant lesdits composés.
• (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase
  作者：John W. Lampe、Yuo Ling Chou、Reda G. Hanna、Susan V. Di Meo、Paul W. Erhardt、Alfred A. Hagedorn、William R. Ingebretsen、Elinor Cantor

  DOI：10.1021/jm00060a012

  日期：1993.4

  Seven 3-alkyl-4-aryl-1,5-dihydro-2H-pyrrol-2-ones were prepared as potential inhibitors of cardiac cAMP phosphodiesterase (PDE). The design of these compounds made use of rolipram, a known inhibitor of the brain cAMP PDE isozyme, as a lead structure and was guided by a model which describes the features required for potent inhibition of the cardiac isozyme. Syntheses for the new compounds are described, together with the results of theoretical and crystallographic studies aimed toward ascertaining their three-dimensional structures. The activities of these compounds as inhibitors of the cardiac and brain cAMP PDE isozymes and their positive inotropic activity in ferret papillary muscle are also reported. Selected compounds were further examined in an in vivo hemodynamic model. One compound,1,5-dihydro-4-[4-(1H-imidazol-1-yl)phenyl]-3-methyl-2H-pyrrol-2-one, was identified as a potent and selective positive inotropic agent and inhibitor of cardiac cAMP PDE.